 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...105106107108109110111112113114115...143144» |
- ||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Trial initiation date, Metastases: ANCHOR-CRC: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (clinicaltrials.gov) - Feb 4, 2019
P2, N=90, Recruiting, Sponsor: Pierre Fabre Medicament
Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: ICRAT: InductionChemo-Radio-Antibody-Treatment (clinicaltrials.gov) - Jan 31, 2019
P2, N=94, Completed, Sponsor: Charite University, Berlin, Germany
Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Jan 2019 Recruiting --> Completed
- || FATE-NK100 / Fate Therap
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jan 31, 2019
P1, N=100, Recruiting, Sponsor: Fate Therapeutics
Recruiting --> Completed Trial completion date: Mar 2020 --> Oct 2022 | Trial primary completion date: Mar 2019 --> Oct 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change: Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=60, Completed, Sponsor: Centre Antoine Lacassagne
Trial completion date: Mar 2020 --> Oct 2022 | Trial primary completion date: Mar 2019 --> Oct 2021 Recruiting --> Completed | N=115 --> 60
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Trial primary completion date: INFIELD: Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Jan 30, 2019
P2, N=72, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed | N=115 --> 60 Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2019 | Trial primary completion date: Dec 2019 --> Jan 2019
- ||| cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change, Metastases: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (clinicaltrials.gov) - Jan 29, 2019
P2, N=110, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2019 | Trial primary completion date: Dec 2019 --> Jan 2019 N=80 --> 110
- || simlukafusp alfa (RG7461) / Roche, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (clinicaltrials.gov) - Jan 28, 2019
P1a/1b, N=205, Recruiting, Sponsor: Hoffmann-La Roche
N=80 --> 110 Trial completion date: Jul 2019 --> May 2020 | Trial primary completion date: Jul 2019 --> May 2020
- ||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 28, 2019
P3, N=645, Active, not recruiting, Sponsor: Array BioPharma
Trial completion date: Jul 2019 --> May 2020 | Trial primary completion date: Jul 2019 --> May 2020 Recruiting --> Active, not recruiting
- ||| anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Combination therapy, Metastases: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPĪ±, With Cetuximab in Subjects With Advanced Solid Cancers (clinicaltrials.gov) - Jan 25, 2019
P1, N=140, Not yet recruiting, Sponsor: Celgene
- || golvatinib (E7050) / Eisai
Trial primary completion date, Combination therapy: E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 23, 2019
P1/2, N=95, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Trial primary completion date: May 2014 --> Jan 2016
- || Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment change: Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 19, 2019
P1, N=240, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: May 2014 --> Jan 2016 N=98 --> 240
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) (clinicaltrials.gov) - Jan 19, 2019
P2, N=30, Recruiting, Sponsor: Shanghai Changzheng Hospital
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (clinicaltrials.gov) - Jan 18, 2019
P3, N=370, Completed, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
N=98 --> 240 Active, not recruiting --> Completed | Trial completion date: May 2019 --> Nov 2018
- | Photofrin (porfimer sodium) / Advanz Pharma
Enrollment open, Metastases: Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jan 18, 2019
P2, N=82, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | Trial completion date: May 2019 --> Nov 2018 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Head-to-Head: Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. (Pubmed Central) - Jan 17, 2019
P3
For patients with HPV-positive oropharyngeal carcinoma, radiotherapy plus cetuximab showed inferior overall survival and progression-free survival compared with radiotherapy plus cisplatin. Radiotherapy plus cisplatin is the standard of care for eligible patients with HPV-positive oropharyngeal carcinoma.
- || tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - Jan 16, 2019
P1/2, N=60, Active, not recruiting, Sponsor: ArQule
Radiotherapy plus cisplatin is the standard of care for eligible patients with HPV-positive oropharyngeal carcinoma. Trial primary completion date: Dec 2018 --> Mar 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed, Enrollment change, Metastases: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 15, 2019
P2/3, N=174, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Dec 2018 --> Mar 2019 Recruiting --> Active, not recruiting | N=605 --> 174
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 14, 2019
P2, N=69, Completed, Sponsor: Eastern Cooperative Oncology Group
Recruiting --> Active, not recruiting | N=605 --> 174 Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion date, Trial primary completion date, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 14, 2019
P2, N=30, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Active, not recruiting --> Completed Trial completion date: Aug 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | New P3 trial, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jan 13, 2019
P3, N=400, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Surgery: Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 9, 2019
P2, N=59, Active, not recruiting, Sponsor: Dwight Heron
Trial completion date: Aug 2018 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC (clinicaltrials.gov) - Jan 9, 2019
P1, N=22, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Phase classification: P1/2 --> P1
- ||||| patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial termination, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) (clinicaltrials.gov) - Jan 7, 2019
P2, N=87, Terminated, Sponsor: Daiichi Sankyo, Inc.
Phase classification: P1/2 --> P1 Completed --> Terminated; Trial was terminated by sponsor due to lack of efficacy.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Jan 3, 2019
P3, N=495, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Trial was terminated by sponsor due to lack of efficacy. Trial completion date: Jan 2019 --> Jan 2020
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 3, 2019
P3, N=930, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jan 2019 --> Jan 2020 Recruiting --> Active, not recruiting
- | Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
New P2 trial, Metastases: ANCHOR-CRC: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (clinicaltrials.gov) - Jan 3, 2019
P2, N=90, Not yet recruiting, Sponsor: Pierre Fabre Medicament
- | Opdivo (nivolumab) / BMS
Enrollment closed, Enrollment change, Metastases: Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=40, Active, not recruiting, Sponsor: RTOG Foundation, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=120 --> 40
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion, Trial completion date, Trial primary completion date, Metastases: ERBITUX (clinicaltrials.gov) - Jan 3, 2019
P2, N=40, Completed, Sponsor: Robert Ferris
Recruiting --> Active, not recruiting | N=120 --> 40 Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2017 | Trial primary completion date: Sep 2017 --> Nov 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
New P2 trial, Metastases: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 3, 2019
P2, N=78, Not yet recruiting, Sponsor: Southwest Oncology Group
- |||||||||| Akalux (cetuximab sarotalocan) / Rakuten Medical
New P3 trial: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy (clinicaltrials.gov) - Jan 2, 2019
P3, N=275, Not yet recruiting, Sponsor: Rakuten Aspyrian, Inc.
- |||| Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: A study to test activity and safety of treatment with avelumab in combination with cetuximab in patients suffering from non-operable squamous cell skin cancer. Eine Studie zur Pr (EUDRACT) - Dec 31, 2018
P2, N=52, Ongoing, Sponsor: Alcedis GmbH
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Surgery, Metastases: SWOG S1613: S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 27, 2018
P2, N=130, Recruiting, Sponsor: Southwest Oncology Group
- || Nanoplatin (demplatin pegraglumer) / NanoCarrier, Orient Europharma
Enrollment closed, Combination therapy, Metastases: NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 26, 2018
P1/2, N=80, Active, not recruiting, Sponsor: NanoCarrier Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2017 | Trial primary completion date: Sep 2017 --> Nov 2015 Recruiting --> Active, not recruiting
- |||| Krazati (adagrasib) / BMS
New P1/2 trial, PD(L)-1 Biomarker, Metastases: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (clinicaltrials.gov) - Dec 24, 2018
P1/2, N=200, Recruiting, Sponsor: Mirati Therapeutics Inc.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2a trial, Combination therapy, Metastases: Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC (clinicaltrials.gov) - Dec 22, 2018
P2a, N=40, Not yet recruiting, Sponsor: Merck KGaA
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2a trial, Metastases: AVETUXIRI: Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (clinicaltrials.gov) - Dec 22, 2018
P2a, N=59, Not yet recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: GBM-LIPO: Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas (clinicaltrials.gov) - Dec 21, 2018
P1, N=9, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly
New P1 trial, Combination therapy, Metastases: CC-95251-ST-001: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - Dec 21, 2018
P1, N=140, Not yet recruiting, Sponsor: Celgene Corporation
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Monotherapy, Metastases: ABORL: Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (clinicaltrials.gov) - Dec 20, 2018
P2, N=25, Recruiting, Sponsor: Centre Leon Berard
Not yet recruiting --> Recruiting Trial completion date: Feb 2020 --> Sep 2021 | Trial primary completion date: Apr 2019 --> Nov 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 20, 2018
P2, N=81, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2020 --> Sep 2021 | Trial primary completion date: Apr 2019 --> Nov 2020 Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Mismatch repair, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Dec 20, 2018
P3, N=308, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial completion date: Sep 2019 --> Feb 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. (Pubmed Central) - Dec 18, 2018
Trial completion date: Sep 2019 --> Feb 2021 Maintenance therapy with simplified biweekly cetuximab is a convenient, effective, and well-tolerated regimen in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: ARTSCANIII: A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (clinicaltrials.gov) - Dec 17, 2018
P3, N=618, Active, not recruiting, Sponsor: Lund University Hospital
Maintenance therapy with simplified biweekly cetuximab is a convenient, effective, and well-tolerated regimen in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Trial primary completion date: Sep 2018 --> Jun 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Dec 16, 2018
P3, N=466, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. (Pubmed Central) - Dec 14, 2018
This association was stronger in patients with left-side CRC (hazard ratio (HR): 1.79 (1.01-3.14); P=0.044 and HR: 2.83 (1.14-7.03); P=0.025, for Fire 3 and JACCRO cohorts, respectively). Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.The Pharmacogenomics Journal advance online publication, 4 October 2016; doi:10.1038/tpj.2016.69.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial: Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer (clinicaltrials.gov) - Dec 13, 2018
P1, N=30, Recruiting, Sponsor: Ahmed A. H. Abdellatif
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery, Metastases: Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck (clinicaltrials.gov) - Dec 12, 2018
P2, N=238, Completed, Sponsor: Radiation Therapy Oncology Group
Rassf1a rs2236947 is a promising biomarker for patients treated with cetuximab plus chemotherapy.The Pharmacogenomics Journal advance online publication, 4 October 2016; doi:10.1038/tpj.2016.69. Active, not recruiting --> Completed
- ||| feladilimab (GSK3359609) / GSK
Enrollment open, Phase classification, Combination therapy, Metastases: GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Dec 12, 2018
P1/2, N=115, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Surgery, Metastases: SAKK 75/08: Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 11, 2018
P3, N=297, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: PALATINUS: Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer (clinicaltrials.gov) - Dec 11, 2018
P2, N=121, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018 Trial completion date: Dec 2018 --> Jun 2019